81 related articles for article (PubMed ID: 28179301)
1. Targeting Prostate Cancer with a Combination of WNT Inhibitors and a Bi-functional Peptide.
Messina CS; Weiher H; Schmidt-Wolf IG
Anticancer Res; 2017 Feb; 37(2):555-559. PubMed ID: 28179301
[TBL] [Abstract][Full Text] [Related]
2. Targeting renal cancer with a combination of WNT inhibitors and a bi-functional peptide.
Koller CM; Kim Y; Schmidt-Wolf IG
Anticancer Res; 2013 Jun; 33(6):2435-40. PubMed ID: 23749892
[TBL] [Abstract][Full Text] [Related]
3. Targeting the Wnt/beta-catenin pathway in multiple myeloma.
Schmeel LC; Schmeel FC; Kim Y; Endo T; Lu D; Schmidt-Wolf IG
Anticancer Res; 2013 Nov; 33(11):4719-26. PubMed ID: 24222106
[TBL] [Abstract][Full Text] [Related]
4. Effect of Wnt inhibitors in pancreatic cancer.
Wall I; Schmidt-Wolf IG
Anticancer Res; 2014 Oct; 34(10):5375-80. PubMed ID: 25275031
[TBL] [Abstract][Full Text] [Related]
5. Targeting cancer with a bi-functional peptide: in vitro and in vivo results.
Meschenmoser K; Kim Y; Franken S; Nowak M; Feldmann G; Bendas G; Wolfgarten M; Messmer D; Schmidt-Wolf IG
In Vivo; 2013; 27(4):431-42. PubMed ID: 23812212
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic potency of Wnt signaling antagonists in the pathogenesis of prostate cancer, current status and perspectives.
Pashirzad M; Shafiee M; Khazaei M; Fiuji H; Ryzhikov M; Soleimanpour S; Hesari A; Avan A; Hassanian SM
J Cell Physiol; 2019 Feb; 234(2):1237-1247. PubMed ID: 30191954
[TBL] [Abstract][Full Text] [Related]
7. Zoledronic acid in combination with serine/threonine phosphatase inhibitors induces enhanced cytotoxicity and apoptosis in hormone-refractory prostate cancer cell lines by decreasing the activities of PP1 and PP2A.
Cirak Y; Varol U; Atmaca H; Kisim A; Sezgin C; Karabulut B; Uzunoglu S; Uslu R; Karaca B
BJU Int; 2012 Dec; 110(11 Pt C):E1147-54. PubMed ID: 22882676
[TBL] [Abstract][Full Text] [Related]
8. [Antitumor and antimetastatic effect of antimicrobial peptide conjugated with tumor homing peptide TMTP1 on the transplanted prostate cancer and gastric cancer in nude mice].
Ma XY; Li S; Luo DF; Liu RH; Lu YP; Wang SX; Ma D; Xi L
Zhonghua Zhong Liu Za Zhi; 2013 Oct; 35(10):737-41. PubMed ID: 24378093
[TBL] [Abstract][Full Text] [Related]
9. Synergistic tumor growth-inhibitory effect of the prostate-specific antigen-activated fusion peptide BSD352 for prostate cancer therapy.
Li B; Zhang LJ; Zhang ZL; Long M; Ren JH; Lin F; Wang X; Wei JX; Dong K; Zhang HZ
Anticancer Drugs; 2011 Mar; 22(3):213-22. PubMed ID: 21150773
[TBL] [Abstract][Full Text] [Related]
10. Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer.
Björkman M; Iljin K; Halonen P; Sara H; Kaivanto E; Nees M; Kallioniemi OP
Int J Cancer; 2008 Dec; 123(12):2774-81. PubMed ID: 18798265
[TBL] [Abstract][Full Text] [Related]
11. In vitro combination treatment with perifosine and UCN-01 demonstrates synergism against prostate (PC-3) and lung (A549) epithelial adenocarcinoma cell lines.
Dasmahapatra GP; Didolkar P; Alley MC; Ghosh S; Sausville EA; Roy KK
Clin Cancer Res; 2004 Aug; 10(15):5242-52. PubMed ID: 15297428
[TBL] [Abstract][Full Text] [Related]
12. Suppression of human prostate tumor growth in mice by a cytolytic D-, L-amino Acid Peptide: membrane lysis, increased necrosis, and inhibition of prostate-specific antigen secretion.
Papo N; Braunstein A; Eshhar Z; Shai Y
Cancer Res; 2004 Aug; 64(16):5779-86. PubMed ID: 15313920
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapeutic agents enhance TRAIL-induced apoptosis in prostate cancer cells.
Munshi A; McDonnell TJ; Meyn RE
Cancer Chemother Pharmacol; 2002 Jul; 50(1):46-52. PubMed ID: 12111111
[TBL] [Abstract][Full Text] [Related]
14. Targeted radiotherapy of prostate cancer with a gastrin-releasing peptide receptor antagonist is effective as monotherapy and in combination with rapamycin.
Dumont RA; Tamma M; Braun F; Borkowski S; Reubi JC; Maecke H; Weber WA; Mansi R
J Nucl Med; 2013 May; 54(5):762-9. PubMed ID: 23492884
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of irofulven monotherapy and in combination with mitoxantrone or docetaxel against human prostate cancer models.
Van Laar ES; Weitman S; MacDonald JR; Waters SJ
Prostate; 2004 Apr; 59(1):22-32. PubMed ID: 14991863
[TBL] [Abstract][Full Text] [Related]
16. Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid.
Ullén A; Lennartsson L; Harmenberg U; Hjelm-Eriksson M; Kälkner KM; Lennernäs B; Nilsson S
Acta Oncol; 2005; 44(6):644-50. PubMed ID: 16165924
[TBL] [Abstract][Full Text] [Related]
17. Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors.
Centenera MM; Gillis JL; Hanson AR; Jindal S; Taylor RA; Risbridger GP; Sutherland PD; Scher HI; Raj GV; Knudsen KE; Yeadon T; ; Tilley WD; Butler LM
Clin Cancer Res; 2012 Jul; 18(13):3562-70. PubMed ID: 22573351
[TBL] [Abstract][Full Text] [Related]
18. Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells.
Ben Sahra I; Laurent K; Giuliano S; Larbret F; Ponzio G; Gounon P; Le Marchand-Brustel Y; Giorgetti-Peraldi S; Cormont M; Bertolotto C; Deckert M; Auberger P; Tanti JF; Bost F
Cancer Res; 2010 Mar; 70(6):2465-75. PubMed ID: 20215500
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of mitogen-elicited signal transduction and growth in prostate cancer with a small peptide derived from the functional domain of DOC-2/DAB2 delivered by a unique vehicle.
Zhou J; Fan J; Hsieh JT
Cancer Res; 2006 Sep; 66(18):8954-8. PubMed ID: 16982733
[TBL] [Abstract][Full Text] [Related]
20. Evidence of a novel docetaxel sensitizer, garlic-derived S-allylmercaptocysteine, as a treatment option for hormone refractory prostate cancer.
Howard EW; Lee DT; Chiu YT; Chua CW; Wang X; Wong YC
Int J Cancer; 2008 May; 122(9):1941-8. PubMed ID: 18183597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]